logo
logo

Kinimmune Wins Highly Competitive Nci Funding To Advance Solid Tumor Immunotherapy For Patients Refractory To Checkpoint Inhibitors

Nov 09, 2022•over 2 years ago
St. LouisBiopharmaTherapeuticsBiotechnologyHealth Care

Description

Kinimmune, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced that the company has received $400k in funding from the National Cancer Institute (NCI) at the National Institutes of Health for its Phase I STTR application, “Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers”. This award will advance the preclinical development of KIN-102, an immunostimulant for intratumoral injection that is designed to turn ‘cold’ tumors ‘hot’ for synergy with immuno-oncology drugs such as checkpoint inhibitors.

Company Information

Company

Kinimmune

Location

St. Louis, Missouri, United States

About

Kinimmune is a clinical-stage pharmaceutical company developing intratumoral immunostimulants for unlocking the full potential of checkpoint inhibition in solid tumors. Precision drug delivery for tuning the immune system. Kinimmune is discovering and developing quick-to-market intratumoral immunotherapies for maximized safety and efficacy in solid tumors. Our immunotherapy products address unmet medical needs by applying our technologies to parent drugs with clinical proof-of-concept or clinically validated pathways. This strategy stands to benefit cancer patients by enabling new therapeutic interventions with proven track records and minimalized safety burdens. With extensive team experience in biotechnology and immunotherapy, we’re working to harness the immune system's potential to fight cancer.

Related People